Gedatolisib Meets Primary Endpoint in Phase 3 for PIK3CA-Mutated Breast Cancer
Celcuity reported that the combination of gedatolisib with fulvestrant and palbociclib in the VIKTORIA-1 study significantly improved progression-free survival in PIK3CA-mutated breast cancer. Data will be submitted to the FDA as a supplemental new drug application.
The VIKTORIA-1 results, published on May 3, 2026, at first glance look like routine oncology news: another drug met its primary endpoint. But when you look at the timing, the trial design, and what's happening simultaneously with competitors, it becomes clear: Celcuity Inc. has just rewritten the rules for the entire PIK3CA-mutated breast cancer segment worth over $7 billion—and did so just weeks before the FDA decides on their application for another population.
The Core: What's Really Happening
VIKTORIA-1 is not just a successful Phase 3. It's a bold clinical bet that paid off twice. The trial tested gedatolisib simultaneously in two independent cohorts: PIK3CA-mutated and PIK3CA wild-type. Both succeeded a few months apart.
In the mutated cohort, gedatolisib combined with fulvestrant and palbociclib outperformed the combination of alpelisib plus fulvestrant—the current second-line standard of care. This was expected, but the significance goes far beyond "another PI3K inhibitor." Gedatolisib is a pan-PI3K/mTORC1/2 inhibitor that targets not only PI3Kα (like alpelisib and inavolisib) but all four class I PI3K isoforms plus mTORC1 and mTORC2.
The key here is the mechanism: when you block only PI3Kα, the tumor quickly activates bypass pathways through other isoforms and mTOR. Gedatolisib blocks the entire PAM pathway completely, and that's fundamentally different biology. As Sarah Hurvitz from Fred Hutchinson Cancer Center put it, this is the first Phase 3 study showing that comprehensive PAM pathway blockade outperforms targeted blockade of a single component.
The second sensation is not even the success in the mutated cohort itself, but that the gedatolisib + fulvestrant doublet (without palbociclib) also showed statistically and clinically significant superiority over alpelisib + fulvestrant. This means patients who cannot continue CDK4/6 inhibitors due to toxicity or progression have an effective option without them. This is clinical flexibility that competitors simply lack.
Timeline and Context
To understand why this news is a bombshell, you need to reconstruct the timeline of the last 18 months.
October 2023: Celcuity announces that VIKTORIA-1 met its primary endpoint in the PIK3CA wild-type cohort. Gedatolisib with fulvestrant ± palbociclib significantly outperformed fulvestrant monotherapy. This was unexpected: no one believed a PI3K inhibitor would work in the absence of a mutation.
January 2026: The FDA accepts gedatolisib's application for PIK3CA wild-type for priority review. The PDUFA date is set for July 17, 2026.
April 2026: Roche receives FDA approval for inavolisib (Itovebi) in first-line PIK3CA-mutated breast cancer—the first-in-class entry into the first line. Roche forecasts peak sales of $2.3 billion.
April 30, 2026: Novartis buys Synnovation Therapeutics and its mutant-selective PI3Kα inhibitor SNV4818 for $2 billion upfront plus $1 billion in milestones. Novartis's alpelisib (Piqray)—the very drug gedatolisib was compared against in VIKTORIA-1—is losing ground: sales fell 6% over the half-year to $229 million.
May 2026: And now Celcuity announces success in the PIK3CA-mutated cohort. Full data will be presented on June 2 at ASCO in a late-breaking session.
Timing here is everything. Celcuity is filing a supplemental new drug application (sNDA) for gedatolisib in the mutated population precisely when: a) their primary application for wild-type is already with the FDA with a decision due in 2.5 months; b) Roche is entering the first-line market; c) Novartis is spending billions on a new generation of selective inhibitors, acknowledging alpelisib's limitations. This is not a coincidence—it's a calculated regulatory strategy.
Who Wins and Who Loses
Winners:
Celcuity Inc. The company's market capitalization after the news reached approximately $7 billion. Citizens analysts raised their stock price target to $160. But the main asset is not current capitalization—it's the portfolio of indications. Gedatolisib now has positive Phase 3 data for both populations—mutated and wild-type. If the FDA approves both indications, the drug will cover virtually the entire HR+/HER2- breast cancer market in the second line, and the VIKTORIA-2 study is already underway in the first line. Plus a separate program for prostate cancer.
Patients with PIK3CA-mutated breast cancer who can no longer take CDK4/6 inhibitors. The doublet without palbociclib showed significant superiority over the current standard—alpelisib plus fulvestrant. This is an option for those who have exhausted the possibility of continuing CDK4/6 therapy.
Oncologists. They get a drug that works regardless of PIK3CA status and offers flexibility in combining with CDK4/6 inhibitors. This simplifies clinical decision-making.
Losers:
Novartis, twice. First, alpelisib (Piqray) was the direct comparator in VIKTORIA-1 and lost. Second, Novartis just invested $2 billion in buying Synnovation, trying to create a new generation of selective PI3Kα inhibitors. But VIKTORIA-1 questions the very premise: is selectivity needed if a pan-inhibitor with comprehensive mTOR blockade shows better results with a manageable safety profile?
Roche with inavolisib. Inavolisib got approval in the first line, but VIKTORIA-1 and the upcoming VIKTORIA-2 threaten that position. If gedatolisib shows superiority in the first line as well, the market Roche is counting on as a growth driver will start shrinking sooner than expected.
AstraZeneca with capivasertib (Truqap). Capivasertib is an AKT inhibitor that has already started eating into alpelisib's share. But gedatolisib, blocking both upstream and downstream AKT targets simultaneously, makes selective AKT inhibition a less attractive strategy.
What the Media Isn't Saying
First: Celcuity is not just a biotech startup. It's a company that licensed gedatolisib from Pfizer. Yes, Pfizer owns the rights to palbociclib (Ibrance)—the very CDK4/6 inhibitor used in combination with gedatolisib. This means gedatolisib's success indirectly supports the Ibrance franchise, which brings Pfizer billions annually. And although Pfizer handed over gedatolisib development to Celcuity, the two companies' interests are deeply intertwined. When Celcuity wins, Pfizer wins twice—as licensor and as manufacturer of the combination drug.
Second: In the VIKTORIA-1 study, the choice of active comparator was asymmetric. In the PIK3CA wild-type cohort, gedatolisib was compared to fulvestrant monotherapy—a deliberately weak standard. But for the mutated cohort, they chose alpelisib + fulvestrant—a real approved standard. This means the study was designed to show superiority over the current standard precisely where it's hardest. And it did. This is not an accident—it's a design that demands serious FDA consideration of the application.
Third: The most underappreciated number is safety. For pan-PI3K inhibitors, hyperglycemia has historically been a problem. But in VIKTORIA-1, the rate of grade 3-4 hyperglycemia was lower than with isoform-specific inhibitors. The discontinuation rate due to side effects was only 2.3% for the triplet. This radically changes the narrative: pan-inhibition does not necessarily mean high toxicity if the molecule is designed correctly. This is an engineering achievement that doesn't make headlines.
Fourth: ASCO 2026 is not just a conference—it's a moment of truth. Full VIKTORIA-1 data for the mutated cohort will be presented by Dr. Hurvitz on June 2 in a late-breaking session. By then, the FDA will have all data in hand, and the decision on the wild-type application (July 17, 2026) may be made with the full picture in mind. This tight timeline leaves competitors no time to respond. If overall survival data also turn out positive, gedatolisib's position will become virtually unassailable.
Forecast: Next 30 Days and 90 Days
30 days (by June 5, 2026):
ASCO 2026 will be a triumph for gedatolisib. Full data will be presented on June 2. I expect strong numbers—both median PFS and risk reduction for progression. The oncology community will start discussing including gedatolisib in NCCN guidelines even before formal FDA approval.
Novartis shares may fall 3-5% as investors assess the implications of gedatolisib's success. The Synnovation deal looks like a belated response to a threat that materialized faster than expected.
Celcuity will likely announce a partnership with a large pharma for gedatolisib commercialization. With data for two populations, the company becomes an attractive acquisition target or strategic alliance partner. The deal price could be $8-12 billion.
90 days (by August 5, 2026):
July 17, 2026—PDUFA date for the FDA decision on gedatolisib in PIK3CA wild-type. Given priority review and compelling data, approval is highly likely. This will be the first pan-PI3K/mTOR inhibitor approved for breast cancer and the first drug approved for the wild-type population.
The supplemental application for the mutated cohort will be filed, and the FDA will likely begin its review. If the agency decides to combine both indications into one decision, it could accelerate patient access.
The main strategic forecast: by August 2026, gedatolisib will become the new second-line standard of care for all HR+/HER2- advanced breast cancer—regardless of PIK3CA status. A company that few took seriously two years ago will own a platform covering up to 70% of all breast cancer cases. And the VIKTORIA-2 study in the first line is the next chapter, which could expand the market by several billion dollars.
The PI3K inhibitor pharmaceutical market, built for decades on the hypothesis "the more selective, the better," has just received proof of the opposite. And now the question is not whether alpelisib and inavolisib will lose the competition—it's how fast.
— Editorial Team
